palivizumab 15 mg/kg

BIOLOGICAL2 trials

Sponsors

MedImmune LLC, AstraZeneca

Conditions

Motavizumab Administration for a Second Season for RSV ProphylaxisRespiratory Syncytial Virus (RSV)

Phase 1

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

CompletedNCT00113490

MedImmune LLCMotavizumab Administration for a Second Season for RSV Prophylaxis

Start: 2005-05-31End: 2006-02-28Updated: 2013-05-22

Unknown Phase

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

RecruitingNCT06851806

AstraZenecaRespiratory Syncytial Virus (RSV)

Start: 2025-12-10End: 2027-02-28Target: 138Updated: 2026-03-18